TY - JOUR
T1 - Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer
AU - Tung, Min Che
AU - Tsai, Chin Shaw Stella
AU - Tung, Jai Nien
AU - Tsao, Tang Yi
AU - Chen, Hung Chang
AU - Yeh, Kun Tu
AU - Liao, Ching Fong
AU - Jiang, Ming Chung
PY - 2009/5
Y1 - 2009/5
N2 - Metastatic markers are highly useful diagnostic and prognostic indicators of cancer metastasis. Herein, we report that secretory CSE1L/CAS, a cellular apoptosis susceptibility protein, is a new marker for metastatic cancer. CAS was colocalized with matrix metalloproteinase-2 in vesicles surrounding the outside of MCF-7 cell membranes, and the COOH-terminal domain of CAS was associated with matrix metalloproteinase-2-containing vesicles. Immunohistochemical staining for CAS was positive in the stroma and gland lumens of human metastatic cancer tissues. CAS was also detected in conditioned medium from B16-F10 melanoma cells and more frequently in the sera of patients with metastatic cancer than in sera from patients with primary cancer. Specifically, the prevalence of serum CAS in serum samples from 146 patients was 58.2% (32 of 55), 32.0% (8 of 25), and 12.1% (8 of 66) for patients with metastatic, invasive, and primary cancers, respectively. Our results suggest that CAS is a secretory protein associated with cancer metastasis, which may have clinical utility in metastatic cancer screening and diagnosis.
AB - Metastatic markers are highly useful diagnostic and prognostic indicators of cancer metastasis. Herein, we report that secretory CSE1L/CAS, a cellular apoptosis susceptibility protein, is a new marker for metastatic cancer. CAS was colocalized with matrix metalloproteinase-2 in vesicles surrounding the outside of MCF-7 cell membranes, and the COOH-terminal domain of CAS was associated with matrix metalloproteinase-2-containing vesicles. Immunohistochemical staining for CAS was positive in the stroma and gland lumens of human metastatic cancer tissues. CAS was also detected in conditioned medium from B16-F10 melanoma cells and more frequently in the sera of patients with metastatic cancer than in sera from patients with primary cancer. Specifically, the prevalence of serum CAS in serum samples from 146 patients was 58.2% (32 of 55), 32.0% (8 of 25), and 12.1% (8 of 66) for patients with metastatic, invasive, and primary cancers, respectively. Our results suggest that CAS is a secretory protein associated with cancer metastasis, which may have clinical utility in metastatic cancer screening and diagnosis.
UR - http://www.scopus.com/inward/record.url?scp=66549089442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66549089442&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-08-0948
DO - 10.1158/1055-9965.EPI-08-0948
M3 - Article
C2 - 19383891
AN - SCOPUS:66549089442
SN - 1055-9965
VL - 18
SP - 1570
EP - 1577
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 5
ER -
